A general approach for the design of covalent protein proximity inducers
This project aims to expand biochemical perturbations using CoLDR chemistry to create small molecules that activate enzymes, modify PTMs, and control protein interactions for therapeutic applications.
Projectdetails
Introduction
Chemical biology has made remarkable strides over recent decades, producing potent and selective inhibitors for many proteins, including essential drug targets. Despite these achievements, however, inhibition has been the primary mode of perturbation (GPCRs notwithstanding), whereas many biological processes are controlled through a rich spectrum of biochemical perturbations.
Research Questions
What if a small molecule could activate an enzyme? Install or remove a post-translational modification (PTM)? Or control its oligomeric state?
Project Goals
The overarching goal of this proposal is to dramatically increase the scope and breadth of perturbations and PTMs one can induce in cells using small molecules. Accomplishing this will have tremendous impact on the ability to investigate numerous cellular processes and holds massive therapeutic potential.
Methodology
To achieve this goal, we will build on our recently developed Covalent Ligand-Directed Release (CoLDR) chemistry, which allows us to tag proteins covalently while preserving their function. Our research will develop:
- A general method to create CoLDR-based probes against a panel of targets, enabling us to harness their activity for selective perturbation of new, non-endogenous substrates.
- Homo-dimeric CoLDR probes to induce selective dimerization of targets. This will allow us to selectively activate targets such as kinases in cells. We will also design protein polymerizers by tethering obligatory homodimers.
- Chimeric proximity inducers that would selectively modify new targets in vitro and in cells.
Expertise
Our group’s experience in covalent chemical biology, proteolysis-targeting chimeras, and the development of the CoLDR platform makes us uniquely positioned to create the next generation of covalent proximity inducers.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.998.744 |
Totale projectbegroting | € 1.998.744 |
Tijdlijn
Startdatum | 1-9-2024 |
Einddatum | 31-8-2029 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- WEIZMANN INSTITUTE OF SCIENCEpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Bioorthogonal Cascade-Targeting: Directing Drugs into Cells with Molecular PrecisionDevelop bioorthogonal cascade-targeting methods for precise, safe, and efficient intracellular delivery of therapeutics, enhancing drug targeting and minimizing collateral damage. | ERC Starting... | € 1.479.321 | 2023 | Details |
Chemical rewiring of E3 ubiquitin ligases as a generalizable therapeutic approachTrickE3 aims to systematically develop monovalent degraders to target undruggable proteins in pancreatic cancer, enhancing drug discovery and expanding the human proteome's targetable space. | ERC Starting... | € 1.499.625 | 2022 | Details |
Designer Condensates for Regulation of Catalytic ProcessesDevelop synthetic biomolecular condensates with tunable properties from peptide libraries to enhance reaction regulation and sustainable drug synthesis in aqueous environments. | ERC Starting... | € 1.498.750 | 2024 | Details |
Protein function regulation through inserts for response to biological, chemical and physical signalsThis project aims to develop a modular platform for engineering proteins to sense and respond to diverse signals, enhancing their functionality for innovative biomedical applications. | ERC Advanced... | € 2.500.000 | 2024 | Details |
Chemical biology of intracellular cholesterol transportChemBioChol aims to develop selective small molecule modulators for cholesterol transport proteins to elucidate their roles in lipid metabolism and potential therapeutic applications in diseases. | ERC Starting... | € 1.499.786 | 2022 | Details |
Bioorthogonal Cascade-Targeting: Directing Drugs into Cells with Molecular Precision
Develop bioorthogonal cascade-targeting methods for precise, safe, and efficient intracellular delivery of therapeutics, enhancing drug targeting and minimizing collateral damage.
Chemical rewiring of E3 ubiquitin ligases as a generalizable therapeutic approach
TrickE3 aims to systematically develop monovalent degraders to target undruggable proteins in pancreatic cancer, enhancing drug discovery and expanding the human proteome's targetable space.
Designer Condensates for Regulation of Catalytic Processes
Develop synthetic biomolecular condensates with tunable properties from peptide libraries to enhance reaction regulation and sustainable drug synthesis in aqueous environments.
Protein function regulation through inserts for response to biological, chemical and physical signals
This project aims to develop a modular platform for engineering proteins to sense and respond to diverse signals, enhancing their functionality for innovative biomedical applications.
Chemical biology of intracellular cholesterol transport
ChemBioChol aims to develop selective small molecule modulators for cholesterol transport proteins to elucidate their roles in lipid metabolism and potential therapeutic applications in diseases.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Inhibitor-Mediated Programming of GlycoformsThe project aims to revolutionize glycan manipulation using Inhibitor-Mediated Programming of Glycoforms (IMProGlyco) to create precision-engineered therapeutic proteins and enhance cellular functions. | EIC Pathfinder | € 2.998.878 | 2025 | Details |
The ProM platform: New ways to drug the undruggablePROSION's ProM-platform aims to unlock and target the undruggable 85% of the human proteome, developing new therapies for hard-to-treat diseases like cancer. | EIC Accelerator | € 2.461.375 | 2022 | Details |
Inhibitor-Mediated Programming of Glycoforms
The project aims to revolutionize glycan manipulation using Inhibitor-Mediated Programming of Glycoforms (IMProGlyco) to create precision-engineered therapeutic proteins and enhance cellular functions.
The ProM platform: New ways to drug the undruggable
PROSION's ProM-platform aims to unlock and target the undruggable 85% of the human proteome, developing new therapies for hard-to-treat diseases like cancer.